After reaching an all-time high of $357 billion in 2019 (as of November 30), life sciences mergers and acquisitions (M&A) are unlikely to surpass that record combined value this year—but the number of deals is likely to bounce back from a year-over-year drop, with cell and gene therapy developers expected to carry out a growing number of those deals, EY has concluded in a report . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge